Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
completed

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

key information

study id #: NCT02286947

condition: Duchenne Muscular Dystrophy

status: completed

purpose:

The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

intervention: Eteplirsen

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT02286947

study details

start date: November 2014

estimated completion: March 2018

phase of development: Phase 2

size / enrollment: 20

study description:
This is an open-label, multi-center study to explore the safety and tolerability of eteplirsen injection in participants with advanced stage DMD with confirmed genetic mutations amenable to treatment by exon 51 skipping.
Participants will be evaluated for inclusion during a Screening/Baseline period of up to 4 weeks. Eligible participants will receive once weekly intravenous (IV) infusions of 30 mg/kg eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations.

primary outcomes:

  • Incidence of Adverse Events [ Time Frame: Up to 144 Weeks ]

secondary outcomes:

  • Number of Participants with Clinical Laboratory Abnormalities (Reported as AEs) [ Time Frame: Up to 144 Weeks ]
  • Number of Participants with Abnormalities in Vital Signs and ECG (Reported as AEs) [ Time Frame: Up to 144 Weeks ]
  • Mean Change from Baseline in Maximum Inspiratory Pressure (MIP) % Predicted [ Time Frame: Baseline to Week 96 ]
  • Mean Change from Baseline in Maximum Expiratory Pressure (MEP) % Predicted [ Time Frame: Baseline to Week 96 ]

inclusion criteria:
• Male 7 - 21 years of age
• Diagnosis of DMD with a mutation that is amenable to exon 51 skipping, confirmed by a genetic report
• Stable dose of oral corticosteroids for at least 24 weeks or has not received corticosteroids for at least 24 weeks
• Non-ambulatory, or incapable of walking >/ = 300 meters on the 6-Minute Walk Test (6MWT).
• Score of < / = 4 on the Brooke Score for Arms and Shoulders.
• Stable cardiac and pulmonary function
• Use of contraceptives for sexually active males throughout the study
• Willing to provide consent and comply with the study

exclusion criteria:
• Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
• Previous treatment with SMT C1100/BMN 195 at any time.
• Previous treatment with drisapersen (PRO051) within the last 6 months.
• Participation in any other DMD interventional clinical study within 12 weeks
• Major change in physiotherapy regimen within the past 3 months
• Major surgery within 3 months
• Presence of other clinically significant illness
• Use of an aminoglycoside antibiotic within 12 weeks or the need for this antibiotic or statin during study
• Forced vital capacity % predicted [FVC % predicted] <40%, or requiring daytime ventilation.
• Require antiarrhythmic and/or antidiuretic therapy for heart failure.
• Have a left ventricular ejection fraction (LVEF) of <40%.
• Prior or ongoing medical condition that could adversely affect the safety of the patient, make it unlikely that the course of treatment would be completed, or impair the assessment of study results.

study contacts

sponsor: Sarepta Therapeutics

investigators: Chris Mix, MD

locations: United States